SimuGen has developed an analysis system that includes a pre-packaged kit that customers can use to test their own compounds. Accompanying client management software then imports the data and sends it to SimuGen's servers for analysis. It produces a dose-response curve for every clinically significant toxicity and also ranks related compounds based on their toxicity profile, allowing medicinal chemists to evaluate potential leads. Finally, clustering analysis reveals how changes to the molecular structure could affect the toxicity profile. The product has been designed to work with relatively few biomarker genes, which simplifies the laboratory procedure and avoids platforms such as microarrays.
2 Oakington Business Park
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.
In this week's episode: 2024’s top-selling drugs; two CEOs call for higher Europe drug prices; diabetes trial win for Lilly’s orforglipron; BMS trial failure in schizophrenia; and an analysis of alliance deal-making last year.
